Revenue Recognition (Tables)

3 Months Ended

Sep. 30, 2018

Revenue Recognition [Abstract]

Schedule of revenues disaggregated by business segment and product lines

	Three months ended September 30, 2018
	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Consolidated Totals
Finished dosage form generic drugs	$	69,213		-		-	$	69,213
Nutraceutical products		11,633		-		-		11,633
Pharmaceutical intermediates		-	$	10,222		-		10,222
Active pharmaceutical ingredients (APIs)		-		28,626		-		28,626
Specialty chemicals		-		-	$	36,221		36,221
Agricultural protection products		-		-		8,490		8,490
	$	80,846	$	38,848	$	44,711	$	164,405

	Three months ended September 30, 2017
	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Consolidated Totals
Finished dosage form generic drugs	$	95,561		-		-	$	95,561
Nutraceutical products		10,454		-		-		10,454
Pharmaceutical intermediates		-	$	10,136		-		10,136
Active pharmaceutical ingredients (API's)		-		26,440		-		26,440
Specialty chemicals		-		-	$	34,020		34,020
Agricultural protection products		-		-		8,644		8,644
	$	106,015	$	36,576	$	42,664	$	185,255

Schedule of activity in the consolidated balance sheet for contra assets and liability for price concessions

	Accruals for Chargebacks, Rebates, Returns and Other Allowances
								Government			Non-Governmental			Sales
		Chargebacks			Returns			Reimbursed Rebates			Rebates & Other			Discounts
Balance at June 30, 2018	$	66,687		$	41,511		$	9,658		$	86,259		$	6,408
Current period provision		184,559			6,465			3,061			43,386			6,584
Credits issued during the period		(157,732	)		(2,220	)		(3,357	)		(30,717	)		(1,991	)
Balance at September 30, 2018	$	93,514		$	45,756		$	9,362		$	98,928		$	11,001